Der Pathologe

, Volume 27, Issue 1, pp 40–46 | Cite as

Hämatologische Nebenwirkungen der Tyrosinkinaseinhibition mit Imatinib

Schwerpunkt: Iatrogene Pathologie

Zusammenfassung

Imatinib (STI571, Gleevec™/Glivec®) und neuere kleinmolekulare Tyrosinkinaseinhibitoren erzielen hohe Ansprechraten bei der Behandlung von chronischer myeloischer Leukämie (CML), gastrointestinalen Stromatumoren (GIST) und seltenen chronischen myeloproliferativen Erkrankungen. Es werden Tyrosinkinase-abhängige Signalwege unterbrochen und Optionen für Neoplasien mit aktivierenden Mutationen im Abelson-, Abl-related-, Kit- oder PDGF-RA- und PDGF-RB-Gen geboten. Allerdings können sekundär therapieresistente mutierte Tumorzellklone auftreten.

Meist wird Imatinib bei nur geringen Nebenwirkungen gut vertragen. Es werden jedoch Toxizitäten (Ödeme, Hautrötungen, Übelkeit oder Myelosuppression) beobachtet. Einige CML-Patienten entwickeln sekundäre Philadelphia- (Ph-)/Bcr-Abl-negative klonale chromosomale Anomalien. Beckenkammbiopsien von CML-Patienten, bei denen in kompletter Remission eine prolongierte Panzytopenie nach Imatinib besteht, zeigen meist eine Markhypoplasie. Morphologisch liegen dann entweder Merkmale einer aplastischen Anämie oder eines myelodysplastischen Syndroms vor, das sich in der Ph-negativen Hämatopoese manifestiert. Vereinzelt kann eine uni- oder multilineäre Dysplasie von einem Blastenexzess begleitet sein und in eine akute Leukämie übergehen. Schwerwiegende hämatologische Nebenwirkungen von Imatinib sind jedoch extrem selten.

Aktuelle Fragen beziehen sich auf die zugrunde liegenden molekularen Mechanismen, besonders auf das Auftreten distinkter Ph-negativer aberranter Klone unter Tyrosinkinaseinhibition.

Schlüsselwörter

Tyrosinkinaseinhibition Myelosuppression Markhypoplasie Myelodysplasie Klonale Aberratonen 

Hematological side effects of tyrosine kinase inhibition using imatinib

Abstract

Imatinib (STI571, Gleevec/Glivec) and other small-molecule tyrosine kinase inhibitors are highly effective in the treatment of chronic myeloid leukemia (CML), gastrointestinal stromal tumors and, for example, eosinophilia-associated chronic myeloproliferative disorders. This molecularly targeted approach disrupts abnormal tyrosine kinase dependent signalling pathways, thus providing a preferred treatment option for selected neoplastic disorders with activating mutations of Abelson-, Abl-related-, Kit-, and platelet-derived growth factor receptor A and B genes. Loss of response to imatinib may be due to an acquired resistance of emerging mutant tumor cell clones.

Therapy is generally well tolerated. However, toxicities including edema, skin rashes, fatigue, nausea and myelosuppression have been reported. Philadelphia/Bcr-Abl-negative clonal chromosomal abnormalities may develop. Bone marrow trephines obtained from CML patients in complete remission with prolonged pancytopenia secondary to imatinib generally show marrow hypoplasia. Morphological features may be in keeping with either aplastic anemia or myelodysplasia developing in Philadelphia-negative hematopoiesis. Single or multilineage myelodysplasia may be accompanied by an excess of blasts and rarely evolves into acute leukemia in CML patients. Severe adverse hematological effects of imatinib are extremely rare.

Current questions involve the molecular mechanisms of hematological side effects of tyrosine kinase inhibitors with special regard to the emergence of distinct aberrant clones.

Keyword

Tyrosine kinase inhibition Myelosuppression Bone marrow hypoplasia Myelodysplasia Clonal aberrations 
This is a preview of subscription content, log in to check access.

Notes

Interessenkonflikt:

Keine Angaben

Literatur

  1. 1.
    Appel S, Balabanov S, Brummendorf TH, Brossart P (2005) Effects of imatinib on normal hematopoiesis and immune activation. Stem Cells 23:1082–1088CrossRefPubMedGoogle Scholar
  2. 2.
    Bacher U, Hochhaus A, Berger U et al. (2005) Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha. Leukemia 19:460–463CrossRefPubMedGoogle Scholar
  3. 3.
    Balabanov S, Appel S, Kanz L et al. (2005) Effect of tyrosine kinase inhibition using imatinib on normal lymphohematopoietic cells. Ann N Y Acad Sci 1044:168–177CrossRefPubMedGoogle Scholar
  4. 4.
    Bartolovic K, Balabanov S, Hartmann U et al. (2003) Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood 103:523–529CrossRefPubMedGoogle Scholar
  5. 5.
    Beham-Schmid C, Apfelbeck U, Sill H et al. (2002) Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood 99:381–383CrossRefPubMedGoogle Scholar
  6. 6.
    Braziel RM, Launder TM, Druker BJ et al. (2002) Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months‘ experience. Blood 100:435–441CrossRefPubMedGoogle Scholar
  7. 7.
    Bumm T, Muller C, Al-Ali HK et al. (2002) Emergence of clonal cytogenetic abnormalities in Ph-cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 101:1941–1949CrossRefPubMedGoogle Scholar
  8. 8.
    Deininger MWN, Druker BJ (2003) Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 55:401–423CrossRefPubMedGoogle Scholar
  9. 9.
    Demetri GD, Mehren M v, Blanke CD et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472–478CrossRefPubMedGoogle Scholar
  10. 10.
    Dewar AL, Zannetino AC, Hughes TP, Lyons AB (2005) Inhibition of c-fms by imatinib. Cell Cycle 4:851–853PubMedGoogle Scholar
  11. 11.
    Druker BJ, O’Brien SG, Cortes J, Radich J (2002) Chronic myelogenous leukemia. Hematology 111–135Google Scholar
  12. 12.
    Fabarius A, Giehl M, Frank O et al. (2005) Induction of centrosome and chromosome aberrations by imatinib in vitro. Leukemia 19:1573–1578CrossRefPubMedGoogle Scholar
  13. 13.
    Hehlmann R, Berger U, Hochhaus A (2005) Chronic myeloid leukemia: a model for oncology. Ann Hematol 84:487–497CrossRefPubMedGoogle Scholar
  14. 14.
    Hochhaus A, Berger U, Hehlmann R (2004) Therapy of chronic myelogeneous leukaemia in 2004. Dtsch Med Wochenschr 129:2122–2127CrossRefPubMedGoogle Scholar
  15. 15.
    Hochhaus A, Hughes T (2004) Clinical resistance to imatinib: mechanisms and implications. Hematol Oncol Clin North Am 18:641–656CrossRefPubMedGoogle Scholar
  16. 16.
    Holtz MS, Bhatia R (2004) Effect of imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cells. Leuk Lymphoma 45:237-45CrossRefPubMedGoogle Scholar
  17. 17.
    Holtz M, Slovak M, Zhang F et al. (2002) Gleevec (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 99:3792–3800CrossRefPubMedGoogle Scholar
  18. 18.
    Jones RL, Judson IR (2005) The development and application of imatinib. Expert Opin Drug Saf 4:183–191CrossRefPubMedGoogle Scholar
  19. 19.
    Kvasnicka HM, Thiele J, Staib P et al. (2004) Therapy-related changes of angiogenesis in Philadelphia chromosome positive chronic myelogenous leukemia. Pathologe 25:127–134CrossRefPubMedGoogle Scholar
  20. 20.
    Lahaye T, Riehm B, Berger U et al. (2005) Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 103:1659–1669CrossRefPubMedGoogle Scholar
  21. 21.
    Lokeshwar N, Kumar L, Kumari M (2005) Severe bone marrow aplasia following imatinib mesylate in a patient with chronic myelogenous leukemia. Leuk Lymphoma 46:781–784PubMedGoogle Scholar
  22. 22.
    Melo JV, Hughes TP, Apperley JF (2003) Chronic myeloid leukemia. Hematology 132–152Google Scholar
  23. 23.
    Michor F, Hughes TP, Iwasa Y et al. (2005) Dynamics of chronic myeloid leukaemia. Nature 435:1267–1270CrossRefPubMedGoogle Scholar
  24. 24.
    O’Brien SG, Guilhot F, Larson RA et al. (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994–1004CrossRefPubMedGoogle Scholar
  25. 25.
    Pardanani A, Tefferi A (2004) Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood 104:1931–1939CrossRefPubMedGoogle Scholar
  26. 26.
    Sacha T, Hochhaus A, Hanfstein B et al. (2003) ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patient who progress to myeloid blast crisis. Leuk Res 27:1163–1166CrossRefPubMedGoogle Scholar
  27. 27.
    Sawayers CL, Hochhaus A, Feldmann E et al. (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99:3530–3539CrossRefPubMedGoogle Scholar
  28. 28.
    Tefferi A (2005) Modern diagnosis and treatment of primary eosinophilia. Acta Haematol 114:52–60CrossRefPubMedGoogle Scholar
  29. 29.
    Terre C, Eclache V, Rousselot P et al. (2004) Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 18:1340–1346CrossRefPubMedGoogle Scholar
  30. 30.
    Thiele J, Kvasnicka HM, Schmitt-Graeff A et al. (2004) Effects of the tyrosine kinase inhibitor imatinib mesylate (STI571) on bone marrow features in patients with chronic myelogenous leukemia. Histopathology 19:1277–1288Google Scholar
  31. 31.
    Thiele J, Kvasnicka HM, Varus E et al. (2004) Regression of the Philadelphia chromosome (bcr/abl)-positive myelo- and megakaryopoiesis after Imatinib (STI571) therapy in chronic myelogenous leukemia (CML). Pathologe 25:428–435CrossRefPubMedGoogle Scholar
  32. 32.
    van der Zwan SM, Dematteo RP (2005) Gastrointestinal stromal tumor: 5 years later. Cancer 104:1781–1788CrossRefPubMedGoogle Scholar
  33. 33.
    Verweij J, Casali PG, Zalcberg J et al. (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364:1127–1134CrossRefPubMedGoogle Scholar
  34. 34.
    Wiedmann MW, Caca K (2005) Molecularly targeted therapy for gastrointestinal cancer. Curr Cancer Drug Targets 5:171–193CrossRefPubMedGoogle Scholar
  35. 35.
    Zalcberg JR, Verweij J, Casali PG et al. (2005) Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 41:1751–1757CrossRefPubMedGoogle Scholar
  36. 36.
    Zaucha JM, Prejzner W, Giebel S et al. (2005) Imatinib therapy prior to myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 36:17–24CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag 2006

Authors and Affiliations

  1. 1.Pathologisches InstitutUniversität Freiburg
  2. 2.Medizinische KlinikKlinikum Mannheim der Universität Heidelberg
  3. 3.Pathologisches InstitutUniversität FreiburgFreiburg

Personalised recommendations